Small Bowel Carcinomas in Coeliac or Crohn’s Disease: Clinico-pathological, Molecular, and Prognostic Features. A Study From the Small Bowel Cancer Italian Consortium

Autor: Claudia Mescoli, Michele Martino, Fausto Sessa, Massimo Rugge, Ombretta Luinetti, Gabriella Nesi, Vincenzo Canzonieri, Alessandro Vanoli, Luca Reggiani Bonetti, Ada Maria Florena, Giovanni Monteleone, Daniela Furlan, Umberto Volta, Paolo Fociani, Vincenzo Villanacci, Antonino Giulio Giannone, Marco Silano, Antonio Di Sabatino, Antonio Maccioni, Paolo Usai, G. Solina, Vittorio Perfetti, Federica Grillo, Maria Cristina Macciomei, Rachele Manca, Stefano Ferrero, Renato Cannizzaro, Aroldo Rizzo, Livia Biancone, Luca Elli, Claudio Papi, Giacomo Caio, Giovanni Latella, Antonio Calabrò, Roberta Cerutti, Marianna Salemme, Paolo Giuffrida, Gianluca M. Sampietro, Gino Roberto Corazza, Paola Migliora, Donatella Santini, Sandro Ardizzone, Augusto Orlandi, Francesco Tonelli, Antonio Ciardi, Catherine Klersy, Carolina Ciacci, Davide Trapani, Renata D'Incà, Francesco Paolo D'Armiento, Marco Paulli, Marco Astegiano, Roberto Caronna, Roberto Fiocca, Luigi Michele Coppola, Paola Alberizzi, Enrico Solcia, Giuseppe Santeusanio, G. Sandri, Roberta Riboni
Přispěvatelé: Vanoli, Alessandro, Sabatino, Antonio Di, Furlan, Daniela, Klersy, Catherine, Grillo, Federica, Fiocca, Roberto, Mescoli, Claudia, Rugge, Massimo, Nesi, Gabriella, Fociani, Paolo, Sampietro, Gianluca, Ardizzone, Sandro, Luinetti, Ombretta, Calabrò, Antonio, Tonelli, Francesco, Volta, Umberto, Santini, Donatella, Caio, Giacomo, Giuffrida, Paolo, Elli, Luca, Ferrero, Stefano, Latella, Giovanni, Ciardi, Antonio, Caronna, Roberto, Solina, Gaspare, Rizzo, Aroldo, Ciacci, Carolina, D'Armiento, FRANCESCO PAOLO, Salemme, Marianna, Villanacci, Vincenzo, Cannizzaro, Renato, Canzonieri, Vincenzo, Bonetti, Luca Reggiani, Biancone, Livia, Monteleone, Giovanni, Orlandi, Augusto, Santeusanio, Giuseppe, Macciomei, Maria C, D'Incà, Renata, Perfetti, Vittorio, Sandri, Giancarlo, Silano, Marco, Florena, Ada M, Giannone, Antonino G, Papi, Claudio, Coppola, Luigi, Usai, Paolo, Maccioni, Antonio, Astegiano, Marco, Migliora, Paola, Manca, Rachele, Martino, Michele, Trapani, Davide, Cerutti, Roberta, Alberizzi, Paola, Riboni, Roberta, Sessa, Fausto, Paulli, Marco, Solcia, Enrico, Corazza, Gino R., Di Sabatino, Antonio, D’Armiento, Francesco P., Reggiani Bonetti, Luca, Macciomei, Maria C., D’Incà, Renata, Florena, Ada M., Giannone, Antonino G., Vanoli A., Di Sabatino A., Furlan D., Klersy C., Grillo F., Fiocca R., Mescoli C., Rugge M., Nesi G., Fociani P., Sampietro G., Ardizzone S., Luinetti O., Calabro A., Tonelli F., Volta U., Santini D., Caio G., Giuffrida P., Elli L., Ferrero S., Latella G., Ciardi A., Caronna R., Solina G., Rizzo A., Ciacci C., D'Armiento F.P., Salemme M., Villanacci V., Cannizzaro R., Canzonieri V., Bonetti L.R., Biancone L., Monteleone G., Orlandi A., Santeusanio G., Macciomei M.C., D'Inca R., Perfetti V., Sandri G., Silano M., Florena A.M., Giannone A.G., Papi C., Coppola L., Usai P., Maccioni A., Astegiano M., Migliora P., Manca R., Martino M., Trapani D., Cerutti R., Alberizzi P., Riboni R., Sessa F., Paulli M., Solcia E., Corazza G.R.
Rok vydání: 2017
Předmět:
Male
0301 basic medicine
Neuroblastoma RAS viral oncogene homolog
Oncology
Survival
Receptor
ErbB-2

Colorectal cancer
medicine.disease_cause
Inflammatory bowel disease
tumour-infiltrating lymphocyte
ErbB-2
0302 clinical medicine
Crohn Disease
Retrospective Studie
Risk Factors
80 and over
Child
Class I Phosphatidylinositol 3-Kinase
Aged
80 and over

Colonic Neoplasm
Settore MED/12 - Gastroenterologia
Crohn's disease
MLH1 methylation
Tumour-infiltrating lymphocytes
Gastroenterology
General Medicine
Middle Aged
Prognosis
Microsatellite instability
MLH1 promoter methylation
030220 oncology & carcinogenesis
Colonic Neoplasms
Survival Analysi
KRAS
Human
Receptor
Adult
Proto-Oncogene Proteins B-raf
medicine.medical_specialty
Prognosi
Class I Phosphatidylinositol 3-Kinases
Settore MED/08 - Anatomia Patologica
NO
Proto-Oncogene Proteins p21(ras)
Young Adult
03 medical and health sciences
Internal medicine
medicine
Carcinoma
Humans
inflammatory bowel disease
microsatellite instability
survival
tumour-infiltrating lymphocytes
neoplasms
Aged
Retrospective Studies
Celiac Disease
Microsatellite Instability
Survival Analysis
Tumor Suppressor Protein p53
business.industry
Tumour-infiltrating lymphocyte
Risk Factor
Cancer
medicine.disease
eye diseases
digestive system diseases
030104 developmental biology
business
Zdroj: Journal of Crohn's and Colitis. 11:942-953
ISSN: 1876-4479
1873-9946
DOI: 10.1093/ecco-jcc/jjx031
Popis: Background and aims An increased risk of small bowel carcinoma [SBC] has been reported in coeliac disease [CD] and Crohn's disease [CrD]. We explored clinico-pathological, molecular, and prognostic features of CD-associated SBC [CD-SBC] and CrD-associated SBC [CrD-SBC] in comparison with sporadic SBC [spo-SBC]. Methods A total of 76 patients undergoing surgical resection for non-familial SBC [26 CD-SBC, 25 CrD-SBC, 25 spo-SBC] were retrospectively enrolled to investigate patients' survival and histological and molecular features including microsatellite instability [MSI] and KRAS/NRAS, BRAF, PIK3CA, TP53, HER2 gene alterations. Results CD-SBC showed a significantly better sex-, age-, and stage-adjusted overall and cancer-specific survival than CrD-SBC, whereas no significant difference was found between spo-SBC and either CD-SBC or CrD-SBC. CD-SBC exhibited a significantly higher rate of MSI and median tumour-infiltrating lymphocytes [TIL] than CrD-SBC and spo-SBC. Among the whole SBC series, both MSI─which was the result of MLH1 promoter methylation in all but one cases─and high TIL density were associated with improved survival at univariable and stage-inclusive multivariable analysis. However, only TILs retained prognostic power when clinical subgroups were added to the multivariable model. KRAS mutation and HER2 amplification were detected in 30% and 7% of cases, respectively, without prognostic implications. Conclusions In comparison with CrD-SBC, CD-SBC patients harbour MSI and high TILs more frequently and show better outcome. This seems mainly due to their higher TIL density, which at multivariable analysis showed an independent prognostic value. MSI/TIL status, KRAS mutations and HER2 amplification might help in stratifying patients for targeted anti-cancer therapy.
Databáze: OpenAIRE